The Life Sciences team advised Flagship Pioneering in Novo Nordisk’s research collaboration with Metaphore Biotechnologies, Inc.
The Metaphore collaboration will leverage its proprietary MIMIC™ platform technology in the discovery and development of up to two multitarget therapeutics leveraging GLP-1R and related biology for obesity management.
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.
The Goodwin team was led by Christopher Denn, Ed Amer, Nancy Urizar, Brittany Morreale, David Sackstein, and Frank Qin, with invaluable assistance from Kingsley Taft, Daniel Karelitz, Susan Lee, Kizzy Jarashow, Artem Skorostensky, and Kat Stavrianidis.
This the third program signed under the previously announced framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.
The Goodwin team who advised on the framework collaboration was led by Kingsley Taft, Nancy Urizar and Dan Karelitz.
For more details, read the press release.